Financhill
Sell
42

PRAX Quote, Financials, Valuation and Earnings

Last price:
$40.31
Seasonality move :
-27.79%
Day range:
$38.21 - $40.84
52-week range:
$26.70 - $91.83
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
84.23x
P/B ratio:
1.82x
Volume:
512.7K
Avg. volume:
522.2K
1-year change:
-25.7%
Market cap:
$811.4M
Revenue:
$8.6M
EPS (TTM):
-$10.27

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
PRAX
Praxis Precision Medicines
$180.2K -$3.14 -57.52% -12.83% $98.82
BTAI
BioXcel Therapeutics
$850K -$1.84 -39.86% -78.16% $48.00
DCGO
DocGo
$100.2M $0.04 -45.2% -91.15% $5.05
IGMS
IGM Biosciences
$4.3M -$0.33 401.41% -42.68% $1.88
NTLA
Intellia Therapeutics
$12.1M -$1.14 -58.66% -12.02% $41.81
ZVRA
Zevra Therapeutics
$24.1M -$0.07 395.13% -53.57% $21.63
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
PRAX
Praxis Precision Medicines
$40.24 $98.82 $811.4M -- $0.00 0% 84.23x
BTAI
BioXcel Therapeutics
$1.78 $48.00 $9.7M -- $0.00 0% 1.99x
DCGO
DocGo
$2.31 $5.05 $235.6M 13.59x $0.00 0% 0.41x
IGMS
IGM Biosciences
$1.35 $1.88 $80.7M -- $0.00 0% 30.49x
NTLA
Intellia Therapeutics
$8.84 $41.81 $915.1M -- $0.00 0% 15.10x
ZVRA
Zevra Therapeutics
$8.00 $21.63 $432.9M -- $0.00 0% 15.67x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
PRAX
Praxis Precision Medicines
-- 0.751 -- 10.45x
BTAI
BioXcel Therapeutics
555.33% -2.205 403.22% 1.58x
DCGO
DocGo
8.55% 2.521 7.04% 2.46x
IGMS
IGM Biosciences
-- -1.217 -- 4.88x
NTLA
Intellia Therapeutics
-- 2.647 -- 5.50x
ZVRA
Zevra Therapeutics
60% 1.216 13.29% 2.35x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
PRAX
Praxis Precision Medicines
-- -$64M -59.11% -59.11% -856.97% -$56.1M
BTAI
BioXcel Therapeutics
-$956K -$13.7M -197.92% -- -4607.48% -$16.3M
DCGO
DocGo
$40.5M -$7.5M 5.8% 6.33% -5.37% $12.2M
IGMS
IGM Biosciences
-- -$39M -159.45% -159.45% -9461.17% -$35.7M
NTLA
Intellia Therapeutics
-- -$136.4M -53.05% -53.05% -1059.87% -$86.2M
ZVRA
Zevra Therapeutics
$10.7M -$15.4M -102.42% -208.85% -150.91% -$16.3M

Praxis Precision Medicines vs. Competitors

  • Which has Higher Returns PRAX or BTAI?

    BioXcel Therapeutics has a net margin of -786.27% compared to Praxis Precision Medicines's net margin of -6378.51%. Praxis Precision Medicines's return on equity of -59.11% beat BioXcel Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    PRAX
    Praxis Precision Medicines
    -- -$2.94 $445.5M
    BTAI
    BioXcel Therapeutics
    -446.73% -$0.32 $18.8M
  • What do Analysts Say About PRAX or BTAI?

    Praxis Precision Medicines has a consensus price target of $98.82, signalling upside risk potential of 145.57%. On the other hand BioXcel Therapeutics has an analysts' consensus of $48.00 which suggests that it could grow by 1936.52%. Given that BioXcel Therapeutics has higher upside potential than Praxis Precision Medicines, analysts believe BioXcel Therapeutics is more attractive than Praxis Precision Medicines.

    Company Buy Ratings Hold Ratings Sell Ratings
    PRAX
    Praxis Precision Medicines
    7 0 1
    BTAI
    BioXcel Therapeutics
    1 1 0
  • Is PRAX or BTAI More Risky?

    Praxis Precision Medicines has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison BioXcel Therapeutics has a beta of 0.078, suggesting its less volatile than the S&P 500 by 92.161%.

  • Which is a Better Dividend Stock PRAX or BTAI?

    Praxis Precision Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioXcel Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Praxis Precision Medicines pays -- of its earnings as a dividend. BioXcel Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PRAX or BTAI?

    Praxis Precision Medicines quarterly revenues are $7.5M, which are larger than BioXcel Therapeutics quarterly revenues of $214K. Praxis Precision Medicines's net income of -$58.7M is lower than BioXcel Therapeutics's net income of -$13.7M. Notably, Praxis Precision Medicines's price-to-earnings ratio is -- while BioXcel Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Praxis Precision Medicines is 84.23x versus 1.99x for BioXcel Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PRAX
    Praxis Precision Medicines
    84.23x -- $7.5M -$58.7M
    BTAI
    BioXcel Therapeutics
    1.99x -- $214K -$13.7M
  • Which has Higher Returns PRAX or DCGO?

    DocGo has a net margin of -786.27% compared to Praxis Precision Medicines's net margin of -2.7%. Praxis Precision Medicines's return on equity of -59.11% beat DocGo's return on equity of 6.33%.

    Company Gross Margin Earnings Per Share Invested Capital
    PRAX
    Praxis Precision Medicines
    -- -$2.94 $445.5M
    DCGO
    DocGo
    33.52% -$0.04 $345.2M
  • What do Analysts Say About PRAX or DCGO?

    Praxis Precision Medicines has a consensus price target of $98.82, signalling upside risk potential of 145.57%. On the other hand DocGo has an analysts' consensus of $5.05 which suggests that it could grow by 118.56%. Given that Praxis Precision Medicines has higher upside potential than DocGo, analysts believe Praxis Precision Medicines is more attractive than DocGo.

    Company Buy Ratings Hold Ratings Sell Ratings
    PRAX
    Praxis Precision Medicines
    7 0 1
    DCGO
    DocGo
    5 1 0
  • Is PRAX or DCGO More Risky?

    Praxis Precision Medicines has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison DocGo has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock PRAX or DCGO?

    Praxis Precision Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DocGo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Praxis Precision Medicines pays -- of its earnings as a dividend. DocGo pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PRAX or DCGO?

    Praxis Precision Medicines quarterly revenues are $7.5M, which are smaller than DocGo quarterly revenues of $120.8M. Praxis Precision Medicines's net income of -$58.7M is lower than DocGo's net income of -$3.3M. Notably, Praxis Precision Medicines's price-to-earnings ratio is -- while DocGo's PE ratio is 13.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Praxis Precision Medicines is 84.23x versus 0.41x for DocGo. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PRAX
    Praxis Precision Medicines
    84.23x -- $7.5M -$58.7M
    DCGO
    DocGo
    0.41x 13.59x $120.8M -$3.3M
  • Which has Higher Returns PRAX or IGMS?

    IGM Biosciences has a net margin of -786.27% compared to Praxis Precision Medicines's net margin of -8894.9%. Praxis Precision Medicines's return on equity of -59.11% beat IGM Biosciences's return on equity of -159.45%.

    Company Gross Margin Earnings Per Share Invested Capital
    PRAX
    Praxis Precision Medicines
    -- -$2.94 $445.5M
    IGMS
    IGM Biosciences
    -- -$0.61 $48.2M
  • What do Analysts Say About PRAX or IGMS?

    Praxis Precision Medicines has a consensus price target of $98.82, signalling upside risk potential of 145.57%. On the other hand IGM Biosciences has an analysts' consensus of $1.88 which suggests that it could grow by 38.89%. Given that Praxis Precision Medicines has higher upside potential than IGM Biosciences, analysts believe Praxis Precision Medicines is more attractive than IGM Biosciences.

    Company Buy Ratings Hold Ratings Sell Ratings
    PRAX
    Praxis Precision Medicines
    7 0 1
    IGMS
    IGM Biosciences
    0 5 1
  • Is PRAX or IGMS More Risky?

    Praxis Precision Medicines has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison IGM Biosciences has a beta of 0.610, suggesting its less volatile than the S&P 500 by 38.975%.

  • Which is a Better Dividend Stock PRAX or IGMS?

    Praxis Precision Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGM Biosciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Praxis Precision Medicines pays -- of its earnings as a dividend. IGM Biosciences pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PRAX or IGMS?

    Praxis Precision Medicines quarterly revenues are $7.5M, which are larger than IGM Biosciences quarterly revenues of $412K. Praxis Precision Medicines's net income of -$58.7M is lower than IGM Biosciences's net income of -$36.6M. Notably, Praxis Precision Medicines's price-to-earnings ratio is -- while IGM Biosciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Praxis Precision Medicines is 84.23x versus 30.49x for IGM Biosciences. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PRAX
    Praxis Precision Medicines
    84.23x -- $7.5M -$58.7M
    IGMS
    IGM Biosciences
    30.49x -- $412K -$36.6M
  • Which has Higher Returns PRAX or NTLA?

    Intellia Therapeutics has a net margin of -786.27% compared to Praxis Precision Medicines's net margin of -1001.23%. Praxis Precision Medicines's return on equity of -59.11% beat Intellia Therapeutics's return on equity of -53.05%.

    Company Gross Margin Earnings Per Share Invested Capital
    PRAX
    Praxis Precision Medicines
    -- -$2.94 $445.5M
    NTLA
    Intellia Therapeutics
    -- -$1.27 $872M
  • What do Analysts Say About PRAX or NTLA?

    Praxis Precision Medicines has a consensus price target of $98.82, signalling upside risk potential of 145.57%. On the other hand Intellia Therapeutics has an analysts' consensus of $41.81 which suggests that it could grow by 373.02%. Given that Intellia Therapeutics has higher upside potential than Praxis Precision Medicines, analysts believe Intellia Therapeutics is more attractive than Praxis Precision Medicines.

    Company Buy Ratings Hold Ratings Sell Ratings
    PRAX
    Praxis Precision Medicines
    7 0 1
    NTLA
    Intellia Therapeutics
    18 6 0
  • Is PRAX or NTLA More Risky?

    Praxis Precision Medicines has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Intellia Therapeutics has a beta of 2.332, suggesting its more volatile than the S&P 500 by 133.227%.

  • Which is a Better Dividend Stock PRAX or NTLA?

    Praxis Precision Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intellia Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Praxis Precision Medicines pays -- of its earnings as a dividend. Intellia Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PRAX or NTLA?

    Praxis Precision Medicines quarterly revenues are $7.5M, which are smaller than Intellia Therapeutics quarterly revenues of $12.9M. Praxis Precision Medicines's net income of -$58.7M is higher than Intellia Therapeutics's net income of -$128.9M. Notably, Praxis Precision Medicines's price-to-earnings ratio is -- while Intellia Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Praxis Precision Medicines is 84.23x versus 15.10x for Intellia Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PRAX
    Praxis Precision Medicines
    84.23x -- $7.5M -$58.7M
    NTLA
    Intellia Therapeutics
    15.10x -- $12.9M -$128.9M
  • Which has Higher Returns PRAX or ZVRA?

    Zevra Therapeutics has a net margin of -786.27% compared to Praxis Precision Medicines's net margin of -296.76%. Praxis Precision Medicines's return on equity of -59.11% beat Zevra Therapeutics's return on equity of -208.85%.

    Company Gross Margin Earnings Per Share Invested Capital
    PRAX
    Praxis Precision Medicines
    -- -$2.94 $445.5M
    ZVRA
    Zevra Therapeutics
    88.66% -$0.69 $99.2M
  • What do Analysts Say About PRAX or ZVRA?

    Praxis Precision Medicines has a consensus price target of $98.82, signalling upside risk potential of 145.57%. On the other hand Zevra Therapeutics has an analysts' consensus of $21.63 which suggests that it could grow by 170.31%. Given that Zevra Therapeutics has higher upside potential than Praxis Precision Medicines, analysts believe Zevra Therapeutics is more attractive than Praxis Precision Medicines.

    Company Buy Ratings Hold Ratings Sell Ratings
    PRAX
    Praxis Precision Medicines
    7 0 1
    ZVRA
    Zevra Therapeutics
    4 0 0
  • Is PRAX or ZVRA More Risky?

    Praxis Precision Medicines has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Zevra Therapeutics has a beta of 1.870, suggesting its more volatile than the S&P 500 by 87.041%.

  • Which is a Better Dividend Stock PRAX or ZVRA?

    Praxis Precision Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zevra Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Praxis Precision Medicines pays -- of its earnings as a dividend. Zevra Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PRAX or ZVRA?

    Praxis Precision Medicines quarterly revenues are $7.5M, which are smaller than Zevra Therapeutics quarterly revenues of $12M. Praxis Precision Medicines's net income of -$58.7M is lower than Zevra Therapeutics's net income of -$35.7M. Notably, Praxis Precision Medicines's price-to-earnings ratio is -- while Zevra Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Praxis Precision Medicines is 84.23x versus 15.67x for Zevra Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PRAX
    Praxis Precision Medicines
    84.23x -- $7.5M -$58.7M
    ZVRA
    Zevra Therapeutics
    15.67x -- $12M -$35.7M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Did Cathie Wood Buy AMD?
Why Did Cathie Wood Buy AMD?

Noted tech investor Cathie Wood has used the recent stock…

Why Did Salesforce Stock Drop After a Strong Quarter?
Why Did Salesforce Stock Drop After a Strong Quarter?

Popular customer relationship management platform provider Salesforce (NYSE:CRM) has been…

Is Adobe Stock a Bargain With AI Tools Driving Growth?
Is Adobe Stock a Bargain With AI Tools Driving Growth?

The share price of American computer software company Adobe (NASDAQ:ADBE)…

Stock Ideas

Buy
71
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 37x

Sell
46
Is AAPL Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 34x

Buy
63
Is NVDA Stock a Buy?

Market Cap: $2.8T
P/E Ratio: 39x

Alerts

Sell
4
CABO alert for May 3

Cable One [CABO] is down 41.98% over the past day.

Buy
55
PDEX alert for May 3

Pro-Dex [PDEX] is down 32.02% over the past day.

Buy
91
TRUP alert for May 3

Trupanion [TRUP] is up 23.52% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock